Literature DB >> 1109725

Hepatitis B antigenemia among blood donors: the changing scene.

B P Moore, R A Perrault.   

Abstract

For the period May 1973 to August 1974 inclusive, the mean prevalence of hepatitis B antigenemia (HBsAg) in all Canadian provinces (per 100,000 population) was, for "first-time" donors, 242 and, for "repeat" donors, 77. A modification of counterimmunoelectrophoresis was used in all 16 regional transfusion centres. The findings confirm the previously noted high prevalence for the Province of Québec and the continuing relatively high prevalence for Canada. The prevalence of HBsAg among donors could be lessened by institution of the following measures: development of a more effective technique for the screening of hepatitis carriers, study of nonparenterally transmitted hepatitis, better reporting of post-transfusion hepatitis, and greater discrimination in prescribing blood and blood components.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109725      PMCID: PMC1956027     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  2 in total

1.  Counter-immunoelectrophoresis for detection of hepatitis B antigen and antibody: a technique for large-scale use.

Authors:  B P Moore; D Meade
Journal:  Can J Public Health       Date:  1972 Sep-Oct

2.  An international proficiency survey for the detection of hepatitis B antigen and antibody in blood donations by counterimmunoelectrophoresis.

Authors:  B P Moore; D Meade; P E Taylor; A E Kelen
Journal:  Vox Sang       Date:  1974-02       Impact factor: 2.144

  2 in total
  2 in total

1.  Hepatitis B follow-up among Indochinese refugees.

Authors:  E S Nicholls; R K Chaudhary; D A Kennedy; J Jung; J W Davies; P Gill
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

2.  Sufficient blood, safe blood: can we have both?

Authors:  Halvard Bönig; Michael Schmidt; Kai Hourfar; Jörg Schüttrumpf; Erhard Seifried
Journal:  BMC Med       Date:  2012-03-23       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.